Psoriatic arthritis: advances in pharmacotherapy based on molecular target.
The progress on the improved understanding of disease pathogenesis and molecular biology has changed the understanding of disease profiles, emphasizing aspects that simple clinical observation could not identify, and demarcating differences between clinical pictures that seemed to overlap. An example of this spectacular evolution is represented by psoriatic arthritis (PsA). This increase of knowledge on pathogenesis has led to an important impact on therapeutic approach. Therapies are now taken into account because their precise target is known. The authors describe treatment guidelines and revisit traditional therapies as well as innovative therapies in PsA.
University Federico II, Rheumatology Research Unit, Department of Clinical and Experimental Medicine , via S. Pansini 5, 80131 - Naples , Italy +39 081 7462063 ; +39 081 5463445 ; rscarpa@unina.it.
Raffaele
R
Scarpa
Luisa
L
Costa
Mariangela
M
Atteno
Antonio
A
Del Puente
Francesco
F
Caso
John M H
JM
Moll
D015535:Arthritis, Psoriatic / Q000188:drug therapy* / Q000276:immunology; D016207:Cytokines / Q000276:immunology; D006801:Humans
D016207:Cytokines